A Pilot Study of PPX in Women With Metastatic Colorectal Cancer
Status:
Completed
Trial end date:
2011-07-01
Target enrollment:
Participant gender:
Summary
This study uses the drug PPX (also called Xyotax and CT-2103) in women with advanced
colorectal cancer. PPX is an experimental drug that has not been approved by the Food and
Drug Administration (FDA). PPX has been shown in the laboratory and in studies in humans to
cause some cancer cells to die and some tumors to shrink. Women in some studies with PPX have
been shown to live longer than the men that receive the drug. Some studies in humans suggest
that estrogen (a hormone found in women) may protect women from getting colorectal cancer and
allow women that do get colorectal cancer to live longer than men that do.
The purpose of this study is to see if women with colorectal cancer and a certain level of
estrogen experience tumor shrinkage after they receive the drug PPX. This study will also
study genes (genes are the cell's blueprint) in participant's tumors and in their blood.
Several genes can affect how people's bodies react to the cancer drugs. We want to see if
these predict response to the study drugs.